Neuralstem to Offer Experimental Stem Cell Therapy in Colorado

Neuralstem plans to offer its experimental stem cell therapy to ALS patients in Colorado under the new “right-to-try” law recently passed in Colorado. According to this law, demonstrating safety is sufficient for administering the drug to terminal patients. As Neuralstem’s human spinal cord-derived stem cell therapy called NSI-566, has been shown in a Phase I trial to be safe in humans (see March 2014 news) it qualifies under the new law. The company has already begun training surgeons on delivery of the therapy. Whether patients will pay for the treatment is yet to be determined.

Neuralstem plans to offer its experimental stem cell therapy to ALS patients in Colorado under the new “right-to-try” law recently passed in Colorado. According to this law, demonstrating safety is sufficient for administering the drug to terminal patients. As Neuralstem’s human spinal cord-derived stem cell therapy called NSI-566, has been shown in a Phase I trial to be safe in humans (see March 2014 news) it qualifies under the new law. The company has already begun training surgeons on delivery of the therapy. Whether patients will pay for the treatment is yet to be determined.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail